{"id":5517,"date":"2025-04-30T07:44:55","date_gmt":"2025-04-30T07:44:55","guid":{"rendered":"https:\/\/echonews.fr\/?page_id=5517"},"modified":"2025-05-03T13:47:38","modified_gmt":"2025-05-03T13:47:38","slug":"urologie-cours","status":"publish","type":"page","link":"http:\/\/echonews.fr\/?page_id=5517","title":{"rendered":"Urologie-cours"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Demo<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Demo<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t<\/i>\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t<\/i>\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

From Bibliography to Educational Materials<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

In the evolving landscape of education, artificial intelligence offers a transformative opportunity for teachers and students alike. This demo aims to illustrate how, by leveraging the capabilities of today’s leading AI technologies<\/strong><\/span>, it is possible to generate a wide array of high-quality educational resources around a single subject.<\/p>

The introduction of AI has multiplied the teacher\u2019s capacity for content creation by a factor still difficult to measure. It dramatically enhances not only the number of materials produced but also their quality and variety.<\/strong><\/span> By using AI tools, educators can now design courses, synthesize complex bibliographies, create detailed lecture slides, develop case studies, formulate quizzes, and offer personalized learning aids\u2014at a speed and depth never before imaginable.<\/p>

Our ambition is to show how these tools can support both the teacher and the student:<\/strong><\/span> assisting educators in the efficient conception and realization of their courses, and providing students with richer, more diverse materials to facilitate a deeper understanding and assimilation of the subject matter.<\/p>

Ultimately, rather than replacing the teacher\u2019s voice,<\/strong><\/span> AI stands as a powerful ally\u2014enabling educators to spend more time focusing on pedagogical strategy, personal mentorship, and the transmission of clinical wisdom that remains irreplaceable.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Wilms Tumor: <\/strong>From Biology to Personalized Therapeutics<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Wilms Tumor:
<\/strong>From Biology to Personalized Therapeutics<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr Anne Dupont<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tHm-envelop<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedin<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tX-twitter<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr Margaret Smith<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tHm-envelop<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedin<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Dr Fran\u00e7ois durand<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tHm-envelop<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tYoutube<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\tLinkedin<\/span>\n\t\t\t\t\t\t<\/i>\t\t\t\t\t<\/a>\n\t\t\t\t<\/span>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bibliography<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tMultifaceted Functions of the Wilms Tumor 1 Protein: From Its Expression in Various Malignancies to Targeted Therapy \/ Qing Nian, Yan Lin, Jinhao Zeng, Yanna Zhang, Rongxing Liu Translational Oncology, Volume 52, 2025, Article 102237 https:\/\/doi.org\/10.1016\/j.tranon.2024.102237<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t
  1. Overview of WT1: Biology and Structure<\/strong><\/li><\/ol>

    WT1 (Wilms Tumor 1) is a zinc finger transcription factor encoded on chromosome 11p13, originally described as a tumor suppressor in pediatric nephroblastoma. However, its function is far more complex: depending on the cellular context, WT1 can act as an oncogene or a tumor suppressor. It regulates gene transcription, cellular differentiation, and organogenesis during development, and maintains homeostasis in adult tissues.<\/p>

    WT1 produces multiple isoforms (+KTS, \u2013KTS) through alternative splicing, each playing distinct roles in gene expression and tumor biology. Its expression is typically restricted to embryonic and select adult tissues like kidney podocytes, but is aberrantly upregulated in a wide array of cancers.<\/p>

    1. Hematologic Malignancies and WT1<\/strong><\/li><\/ol>

      a) Acute Myeloid Leukemia (AML)<\/strong><\/p>

      WT1 is mutated in ~15% of AML patients and often co-mutated with FLT3-ITD or NPM1. These mutations influence the Wnt\/\u03b2-catenin, TET2, and MEG3 pathways, promote leukemogenesis, and impact response to chemotherapy. WT1 overexpression enhances stemness, self-renewal, and resistance to apoptosis.<\/p>

      b) Myelodysplastic Syndromes (MDS)<\/strong><\/p>

      WT1 is overexpressed in ~50% of MDS patients. It is associated with poor prognosis and disease progression. WT1 interacts synergistically with FLT3 mutations, contributing to transformation to AML.<\/p>

      c) T-cell Acute Lymphoblastic Leukemia (T-ALL)<\/strong><\/p>

      WT1 mutations (~10% of T-ALL cases) activate the IL7R-JAK-STAT pathway and impair TP53-mediated DNA damage response. Co-occurrence with NOTCH1\/FBXW7\/FLT3 mutations suggests an oncogenic synergy.<\/p>

      d) Chronic Myeloid Leukemia (CML)<\/strong><\/p>

      WT1 expression is increased in advanced CML via BCR-ABL1 activation. It contributes to resistance against tyrosine kinase inhibitors like imatinib by interfering with apoptosis and gene regulation through the WT1\/ZNF224\/c-Myc axis.<\/p>

      e) Acute Promyelocytic Leukemia (APL)<\/strong><\/p>

      WT1 interacts with the PML-RARA fusion protein, altering differentiation. Noncoding mutations in WT1 may also contribute to leukemogenesis.<\/p>

      1. WT1 in Solid Tumors<\/strong><\/li><\/ol>

        a) Lung Cancer<\/strong><\/p>

        WT1 promotes VEGF isoform expression and angiogenesis. It may serve as a target to reverse resistance to EGFR inhibitors in non-small-cell lung cancer (NSCLC).<\/p>

        b) Breast Cancer<\/strong><\/p>

        WT1 isoforms have distinct roles in ER-positive and triple-negative breast cancer. They affect ER\u03b1 signaling, promote EMT and metastasis, and may predict resistance to hormone therapy. WT1-targeted vaccines in combination with endocrine therapy show promising early results.<\/p>

        c) Neuroblastoma<\/strong><\/p>

        In neuroblastoma, WT1 often functions as a tumor suppressor. It promotes differentiation through inhibition of PI3K\/Akt and MAPK\/ERK pathways. However, high WT1 is paradoxically associated with poor prognosis in non-MYCN-amplified tumors.<\/p>

        d) Prostate Cancer<\/strong><\/p>

        WT1 downregulates E-cadherin, facilitating migration and metastasis. It also modulates VEGF transcription and androgen receptor activity, influencing hormone resistance.<\/p>

        e) Hepatocellular and Pancreatic Cancer<\/strong><\/p>

        WT1 influences Wnt\/\u03b2-catenin, JAK2\/STAT3, and NF-\u03baB pathways. It promotes tumorigenesis, invasion, and modulates immune escape mechanisms. In pancreatic ductal adenocarcinoma, it interacts with STAT3 and miR-216a\/KRT7, facilitating metastasis.<\/p>

        f) Ovarian Cancer<\/strong><\/p>

        WT1 is highly expressed in serous subtypes and promotes EMT via ERK1\/2 and E-calmodulin pathways. It is involved in mesenchymal\u2013epithelial transitions (MET) and cancer stem cell formation through interaction with EZH2.<\/p>

        g) Astrocytomas\/Glioblastoma<\/strong><\/p>

        WT1 contributes to glioblastoma aggressiveness and poor prognosis. Its inhibition enhances radiosensitivity, and WT1 vaccines elicit cytotoxic immune responses in glioma patients.<\/p>

        1. WT1 as a Therapeutic Target<\/strong><\/li><\/ol>

          a) Chemical Inhibitors<\/strong><\/p>

          Agents like 17-AAG (Hsp90 inhibitor), TMPyP4 (G-quadruplex stabilizer), and daunorubicin reduce WT1 expression. These agents inhibit tumor growth and increase chemosensitivity in WT1-overexpressing malignancies.<\/p>

          b) Natural Products<\/strong><\/p>

          Compounds such as bufalin, shikonin, aloin, curcumin, and resveratrol suppress WT1 expression and modulate apoptosis pathways. Marine-derived molecules also show potential in WT1 inhibition.<\/p>

          c) Kinase Modulators<\/strong><\/p>

          GSK3\u03b2 affects WT1 stability and degradation. Dasatinib is proposed as a modulator to reduce cytokine release syndrome in combination therapies.<\/p>

          1. Immunotherapy Strategies<\/strong><\/li><\/ol>